The immunosuppressant everolimus, carried aboard droplets of fat (liposomes) to lung cells may ease scarring and inflammation linked to systemic scleroderma (SSc), a study with aged mice found.

The findings provide “preclinical evidence of everolimus as an efficient drug to reduce lung fibrosis [scarring] and inflammation,” its researchers wrote.

The study, “Everolimus targeted nanotherapy reduces inflammation and fibrosis in scleroderma-related interstitial lung disease (SSc-ILD) developed by PSGL-1 deficient mice,” was published in the British Journal of Pharmacology by a team of researchers in Europe.

Scleroderma is caused in part by an overactive immune system that turns against the body’s own tissues. This results in inflammation that damages the skin and can sometimes affect blood vessels and internal organs.

Read the full article at sclerodermanews.com